Clinical Trial: A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)

U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07141004) titled 'A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)' on Aug. 21.

Brief Summary: The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.

Study Start Date: Aug. 12

Study Type: INTERVENTIONAL

Condition: Arthritis, Psoriatic

Intervention: DRUG: Guselkumab

Guselkumab will be administered as subcutaneous injection.

Recruitment Status: RECRUITING

Sponsor...